State Initiatives | Association for Accessible Medicines

Lisa Steelman Joins AAM as Vice President, State Government Affairs

WASHINGTON, DC (August 10, 2020) — Today Lisa Steelman is joining the Association for Accessible Medicines (AAM). As Vice President, State Government Affairs, she serves as a senior strategist and lobbyist in partnership with the Senior Vice President, Government Affairs, Chris Bowlin, and other members of the State Government Affairs team to represent AAM and its member companies’ interests before state legislators, regulators and other state and local governmental entities.

Read more about Lisa Steelman Joins AAM as Vice President, State Government Affairs

Stories and Data: How AAM Equips Advocates in the States

Drug prices matter to patients and their families. If a medicine isn’t affordable, it isn’t accessible. David Mitchell, founder of Patients for Affordable Drugs, has called drug pricing “a genuinely bipartisan issue.” The Association for Accessible Medicines (AAM) and our allies see federal and state solutions.

Read more about Stories and Data: How AAM Equips Advocates in the States

AAM Response to CA Governor Newsom Signing AB 824

WASHINGTON, DC (October 8, 2019)--

"As the Federal Trade Commission has found, recent patent litigation settlements have overwhelmingly accelerated the launch of more affordable generic and biosimilar medicines prior to the branded drug's patent expiration date.

Read more about AAM Response to CA Governor Newsom Signing AB 824

A Generic Summer Savings Tour: How Did Your State Do?

The 11th edition of the Association for Accessible Medicines' annual Access and Savings Report (see summary) reveals how much money American patients and taxpayers saved in 2018 through competition from generic drugs and biosimilar alternatives to brand-name biologic medicines. The report provides data by state, based on findings by IQVIA. We’re releasing a detailed publication later this summer.

Some notable facts from the state data:

Read more about A Generic Summer Savings Tour: How Did Your State Do?

Patient Victory: Supreme Court Denies Review of Drug Pricing Law HB 631

WASHINGTON, DC (February 19, 2019) – Today’s decision is a victory for patients who depend on a strong national market for generic and biosimilar medicines. Maryland’s law would have allowed one state to dictate prices in the competitive national market for generic medicines that saved patients and taxpayers $265 billion in 2017.

Read more about Patient Victory: Supreme Court Denies Review of Drug Pricing Law HB 631

AAM Receives Platinum and Gold Recognition from Hermes Creative Awards

The Association of Marketing and Communication Professionals (AMCP) has given the Association for Accessible Medicines (AAM) Platinum and Gold awards for recent marketing campaigns. The Hermes Creative Awards, administered and judged by AMCP, recognizes creative excellence in traditional and emerging media.

Read more about AAM Receives Platinum and Gold Recognition from Hermes Creative Awards

Tara Ryan Joins AAM as Vice President, State Government Affairs

WASHINGTON DC (May 14, 2018) – Tara Ryan joins the Association for Accessible Medicines’ (AAM) State Government Affairs team as Vice President, State Government Affairs, effective today. She reports to Chris Bowlin, Senior Vice President, Government Affairs.

Read more about Tara Ryan Joins AAM as Vice President, State Government Affairs

Amend Connecticut House Bill 5384

Don’t Harm Patient Access to FDA-Approved Generic Medicines by Chilling Generic Drug Competition

Everyone supports containing skyrocketing prescription drug prices but Connecticut H.B. 5384 will actually just make the problem worse for Connecticut patients and our economy. Generic medicines saved Connecticuters $2.9 billion in the year 2016 alone.

Read more about Amend Connecticut House Bill 5384

Oppose Louisiana House Bill 243

Don’t Harm Patient Access To FDA-Approved Generic Medicines By Chilling Generic Drug Competition

Everyone supports containing skyrocketing prescription drug prices, but H.B. 243 is misguided and would actually make the problem worse for Louisiana patients and our economy. The same bill became law in Maryland but was later found unconstitutional.

Read more about Oppose Louisiana House Bill 243

AAM Statement on U.S. Court of Appeals Ruling on Maryland HB 631

WASHINGTON, DC (April 13, 2018) — Today, the United States Court of Appeals for the Fourth Circuit ruled that Maryland’s HB 631 is unconstitutional because it violates the Commerce Clause of the U.S. Constitution. As AAM has always maintained, this law, and any others modeled from it, would harm patients because the law would reduce generic drug competition and choice, thus resulting in an overall increase in drug costs due to increased reliance upon more-costly branded medications.

Chester "Chip" Davis, Jr. President and CEO, Association for Accessible Medicines

Read more about AAM Statement on U.S. Court of Appeals Ruling on Maryland HB 631